Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012

Maha Hussain*, Stephanie Daignault-Newton, Przemyslaw W. Twardowski, Costantine Albany, Mark N. Stein, Lakshmi P. Kunju, Javed Siddiqui, Yi Mi Wu, Dan Robinson, Robert J. Lonigro, Xuhong Cao, Scott A. Tomlins, Rohit Mehra, Kathleen A. Cooney, Bruce Montgomery, Emmanuel S. Antonarakis, Daniel H. Shevrin, Paul G. Corn, Young E. Whang, David C. SmithMegan V. Caram, Karen E. Knudsen, Walter M. Stadler, Felix Y. Feng, Arul M. Chinnaiyan

*Corresponding author for this work

Research output: Contribution to journalArticle

66 Scopus citations

Abstract

Purpose To determine whether cotargeting poly (ADP-ribose) polymerase-1 plus androgen receptor is superior to androgen receptor inhibition in metastatic castration-resistant prostate cancer (mCRPC) and whether ETS fusions predict response. Patients and Methods Patients underwent metastatic site biopsy and were stratified by ETS status and randomly assigned to abiraterone plus prednisone without (arm A) or with veliparib (arm B). Primary objectives were: confirmed prostate-specific antigen (PSA) response rate (RR) and whether ETS fusions predicted response. Secondary objectives were: safety, measurable disease RR (mRR), progression-free survival (PFS), and molecular biomarker analysis. A total of 148 patients were randomly assigned to detect a 20% PSA RR improvement. Results A total of 148 patients with mCRPC were randomly assigned: arm A, n = 72; arm B, n = 76. There were no differences in PSA RR (63.9% v 72.4%; P = .27), mRR (45.0% v 52.2%; P = .51), or median PFS (10.1 v 11 months; P = .99). ETS fusions did not predict response. Exploratory analysis of tumor sequencing (80 patients) revealed: 41 patients (51%) were ETS positive, 20 (25%) had DNA-damage repair defect (DRD), 41 (51%) had AR amplification or copy gain, 34 (43%) had PTEN mutation, 33 (41%) had TP53 mutation, 39 (49%) had PIK3CA pathway activation, and 12 (15%) had WNT pathway alteration. Patients with DRD had significantly higher PSA RR (90% v 56.7%; P = .007) and mRR (87.5% v 38.6%; P = .001), PSA decline $ 90% (75% v 25%; P = .001), and longer median PFS (14.5 v 8.1 months; P = .025) versus those with wild-type tumors. Median PFS was longer in patients with normal PTEN (13.5 v 6.7 months; P = .02), TP53 (13.5 v 7.7 months; P = .01), and PIK3CA (13.8 v 8.3 months; P = .03) versus those with mutation or activation. In multivariable analysis adjusting for clinical covariates, DRD association with PFS remained significant. Conclusion Veliparib and ETS status did not affect response. Exploratory analysis identified a novel DRD association with mCRPC outcomes.

Original languageEnglish (US)
Pages (from-to)991-999
Number of pages9
JournalJournal of Clinical Oncology
Volume36
Issue number10
DOIs
StatePublished - Apr 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012'. Together they form a unique fingerprint.

  • Cite this

    Hussain, M., Daignault-Newton, S., Twardowski, P. W., Albany, C., Stein, M. N., Kunju, L. P., Siddiqui, J., Wu, Y. M., Robinson, D., Lonigro, R. J., Cao, X., Tomlins, S. A., Mehra, R., Cooney, K. A., Montgomery, B., Antonarakis, E. S., Shevrin, D. H., Corn, P. G., Whang, Y. E., ... Chinnaiyan, A. M. (2018). Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: Results from NCI 9012. Journal of Clinical Oncology, 36(10), 991-999. https://doi.org/10.1200/JCO.2017.75.7310